Completed PHASE1 INTERVENTIONAL 4-arm NCT06435676

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions Overweight or Obesity; Type 2 Diabetes

Interventions HRS9531 Placebo

Updated 4 times since 2024 Last updated: May 21, 2025 Started: Jun 4, 2024 Primary completion: Oct 8, 2024 Completion: Oct 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Overweight or Obesity; Type 2 Diabetes, this trial is completed. The trial is conducted by Fujian Shengdi Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Shengdi Pharmaceutical Co., Ltd.

Data source: Fujian Shengdi Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hefei, China